LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...
The AHA recommended whole exome or whole genome sequencing as first-line diagnostic tools for mitochondrial diseases.
According to a recent AHA Scientific Statement, despite ongoing limitations, recent advances in genomic sequencing ...
At the onset of diabetic cardiomyopathy, Trdn-as expression increases, which regulates the methylation of Casq2 mRNA mediated by METTL14, thus increasing the stability and expression of Casq2 mRNA.
MA-5 is a therapeutic intervention for mitochondrial disease that has been demonstrated to ameliorate severe symptoms such as neurological disorders, renal dysfunction, hepatic dysfunction and motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback